Home › Neoplasm ayon sa Histologic Type
Pag-aaral pangklinika para sa Neoplasm ayon sa Histologic Type na nagre-recruit sa U.S.
12 pag-aaral para sa Neoplasm ayon sa Histologic Type ang nagre-recruit ng mga kalahok sa mga site sa buong Estados Unidos.
Mga lungsod na may pinakamaraming pag-aaral
- Atlanta, GA5 pag-aaral
- Boston, MA5 pag-aaral
- Los Angeles, CA4 pag-aaral
- Chicago, IL4 pag-aaral
- Houston, TX4 pag-aaral
- San Francisco, CA3 pag-aaral
- Baldwin Park, CA3 pag-aaral
- St. Louis, MO3 pag-aaral
- Nashville, TN3 pag-aaral
- Dallas, TX3 pag-aaral
- New York City, NY3 pag-aaral
- Clifton, NJ3 pag-aaral
- Tampa, FL3 pag-aaral
Ayos sa estado
- California7 pag-aaral
- Florida6 pag-aaral
- Georgia6 pag-aaral
- Illinois4 pag-aaral
- Massachusetts5 pag-aaral
- Michigan4 pag-aaral
- Missouri4 pag-aaral
- New Jersey5 pag-aaral
- New York3 pag-aaral
- Ohio4 pag-aaral
- Tennessee4 pag-aaral
- Texas6 pag-aaral
Mga pag-aaral na kamakailan lamang in-update
Opisyal na teksto ng pag-aaral (English)
uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Set 29, 2026 · NCT05874921Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
Nagre-recruitPhase 1/2
Edad 18 hanggang 99 · Lahat ng kasarian · Na-update Set 28, 2026 · NCT07416188HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
Nagre-recruitPhase 1
36 Months – 22 Years · Lahat ng kasarian · Na-update Set 4, 2026 · NCT03911388A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 28, 2026 · NCT07075185Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 20, 2026 · NCT06001788A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 19, 2026 · NCT04104776Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 29, 2026 · NCT04198766Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 7, 2026 · NCT07216443Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 4, 2026 · NCT06463665A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
Nagre-recruitPhase 1/2
Edad 12 pataas · Lahat ng kasarian · Na-update May 27, 2026 · NCT03093116Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Nagre-recruit
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 30, 2026 · NCT05297734A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study
Nagre-recruitPhase 1
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Ago 2, 2024 · NCT06271252Mula sa ClinicalTrials.gov, na-kuha noong Set 30, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.